← 返回

抗癌放(免疫)治疗期间的免疫调节

英文原题:Immune modulation during anti-cancer radio(immuno)therapy.

查看英文原题

Immune modulation during anti-cancer radio(immuno)therapy.

PubMed 2023/07/26(内容时间) Int Rev Cell Mol Biol

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌症可影响人体所有器官和组织,是导致死亡的主要原因之一,也是提高预期寿命的障碍。肿瘤学领域的一项显著突破是将免疫系统纳入抗癌斗争,这可能延长生命并提供长期获益。自19世纪和20世纪初以来,Wilhelm Busch、William B. Coley和Paul Ehrlich就对“免疫治疗”的概念进行了讨论。这涉及不同的方法,包括疫苗、非特异性细胞因子和过继性细胞疗法。然而,尽管近年来取得了进展,如何选择最佳治疗方案或如何选择最佳组合以改善临床结局的问题,对科学家和临床医生而言仍然具有现实意义。超过半数的癌症患者接受放疗(RT)作为其治疗的一部分。随着RT和免疫治疗方法的进步,考虑如何利用放疗增强免疫治疗以及反之亦然,并研究这些疗法的联合是否有益,是合理的。在本章中,我们将讨论免疫系统如何应对癌细胞和不同的癌症疗法,重点关注RT与免疫治疗的联合(放射免疫治疗,RIT)。

展开英文摘要原文

Cancer can affect all human organs and tissues and ranks as a prominent cause of death as well as an obstruction to increasing life expectancy. A notable breakthrough in oncology has been the inclusion of the immune system in fighting cancer, potentially prolonging life and providing long-term benefits. The concept of "immunotherapy" has been discussed from the 19th and early 20th centuries by Wilhelm Busch, William B. Coley and Paul Ehrlich. This involves distinct approaches, including vaccines, non-specific cytokines and adoptive cell therapies.

However, despite the advances made in recent years, questions on how to select the best therapeutic options or how to select the best combinations to improve clinical outcomes are still relevant for scientists and clinicians. More than half of cancer patients receive radiotherapy (RT) as part of their treatment.

With the advances in RT and immunotherapy approaches, it is reasonable to consider how to enhance immunotherapy with radiation and vice versa, and to investigate whether combinations of these therapies would be beneficial. In this chapter, we will discuss how the immune system responds to cancer cells and different cancer therapies with a focus on combination of RT and immunotherapy (radioimmunotherapy, RIT).

论文信息

作者
Irianto T、Gaipl US、Rückert M
第一作者单位
Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.Germany
通讯作者单位
Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. Electronic address: michael.rueckert@uk-erlangen.de.Germany
文献类型
非美国政府资助研究
期刊
International review of cell and molecular biology2024
原文标识
PubMed 38225105 · DOI 10.1016/bs.ircmb.2023.05.008